Glagow-headquartered EnteroBiotix has received a £19 million funding to support its clinical trials on irritable bowel syndrome (IBS).
According to The Scotsman, the company will use the proceeds for extensive clinical trials of microbiome medication, EBX-102-02 for IBS.
IBS is a serious health condition which affects one in ten people in the world, with women at greater risk.
The latest funding round was led by life science investor Thairm Bio and the Scottish National Investment Bank, and participation from existing investors.
EnteroBiotix has so far raised £65 million since it was set up in 2017.
The latest trial involving around 300 patients has commenced, and EnteroBiotix chief executive James McIlroy claimed the new drug is acts efficiently than usual probiotics with more than 400 species of strains that will restore gut microbiome.
The company is also doing research on liver cirrhosis and blood cancer.
